Published in BMC Neurol on March 10, 2016
Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis. Neurol Neuroimmunol Neuroinflamm (2017) 0.75
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord (2017) 0.75
Multiple sclerosis. Lancet (2008) 13.77
Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol (1993) 9.97
IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature (2008) 7.00
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med (2008) 6.86
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol (2005) 4.04
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today (1995) 3.60
Human T-cell receptor variable gene segment families. Immunogenetics (1995) 2.86
HIV and autoimmunity. Autoimmun Rev (2002) 2.83
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol (2005) 2.74
The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol (2005) 2.44
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol (1999) 2.28
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity. Neurology (2014) 2.27
Autoimmunity during lymphopenia: a two-hit model. Clin Immunol (2006) 2.01
Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet (2001) 1.96
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol (2007) 1.92
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest (2009) 1.87
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology (2009) 1.75
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain (2010) 1.71
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet (1994) 1.59
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1997) 1.54
Release from regulatory T cell-mediated suppression during the onset of tissue-specific autoimmunity is associated with elevated IL-21. J Immunol (2008) 1.42
Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A (2013) 1.38
CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain (2009) 1.33
Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology (2012) 1.30
B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol (2009) 1.26
Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One (2012) 1.24
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry (2014) 1.21
HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood (2007) 1.19
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood (2002) 1.09
Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis. Ann Neurol (2009) 1.08
Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci (2009) 1.07
Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis. J Neurol (2008) 1.05
Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun (2011) 1.04
Characterization of the 4C8 antigen involved in transendothelial migration of CD26(hi) T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med (1999) 1.02
Development and pharmacological modulation of embryonic stem cell-derived neuronal network activity. Exp Neurol (2007) 1.02
Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci (2015) 0.98
Emerging concepts in autoimmune encephalomyelitis beyond the CD4/T(H)1 paradigm. Ann Anat (2010) 0.96
Migration of multiple sclerosis lymphocytes through brain endothelium. Arch Neurol (2002) 0.93
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg (2004) 0.91
Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.89
CAMPATH-IH in multiple sclerosis. Mult Scler (1996) 0.87
Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. Am J Pathol (2010) 0.84
Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol (2016) 1.46
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol (2016) 0.94
TREK-king the blood-brain-barrier. J Neuroimmune Pharmacol (2014) 0.80
The role of ion channels in malignant brain tumors. J Neurooncol (2015) 0.76